Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

Open access
Sabbatino, Francesco, Villani, Vincenzo, Yearley, Jennifer H., Deshpande, Vikram, Cai, Lei, Konstantinidis, Ioannis T., Moon, Christina, Nota, Sjoerd, Wang, Yangyang, Al-Sukaini, Ahmad, Zhu, Andrew X., Goyal, Lipika, Ting, David T., Bardeesy, Nabeel, Hong, Theodore S., Fernandez-del Castillo, Carlos, Tanabe, Kenneth K., Lillemoe, Keith D., Ferrone, Soldano, Ferrone, Cristina R.·2016·Clinical Cancer Research

Abstract

Purpose: More effective therapy is needed for intrahepatic cholangiocarcinoma (ICC). The encouraging clinical results obtained with checkpoint molecule-specific monoclonal antibodies (mAb) have prompted us to investigate whether this type of immunotherapy may be applicable to ICC. The aims of this study were to determine whether (i) patients mount a T-cell immune response to their ICC, (ii) checkpoint molecules are expressed on both T cells and tumor cells, and (iii) tumor cells are susceptible to recognition by cognate T cells. Experimental Design: Twenty-seven ICC tumors were analyzed for (i) lymphocyte infiltrate, (ii) HLA class I and HLA class II expression, and (iii) PD-1 and PD-L1 expression by T cells and ICC cells, respectively. The results of this analysis were correlated with the clinicopathologic characteristics of the patients investigated. Results: Lymphocyte infiltrates were identified in all tumors. PD-L1 expression and HLA class I antigen expression by ICC cells was observed in 8 and 11, respectively, of the 27 tumors analyzed. HLA class I antigen expression correlated with CD8+ T-cell infiltrate. Furthermore, positive HLA class I antigen expression in combination with negative/rare PD-L1 expression was associated with favorable clinical course of the disease. Conclusions: ICC patients are likely to mount a T-cell immune response against their own tumors. Defects in HLA class I antigen expression in combination with PD-L1 expression by ICC cells provide them with an immune escape mechanism. This mechanism justifies the implementation of immunotherapy with checkpoint molecule-specific mAbs in patients bearing ICC tumors without defects in HLA class I antigen expression. Clin Cancer Res; 22(2); 470–8. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0715

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 216

Metadata

Authors
Sabbatino, F., Villani, V., Yearley, J. H., Deshpande, V., Cai, L., Konstantinidis, I. T., Moon, C., Nota, S., Wang, Y., Al-Sukaini, A., Zhu, A. X., Goyal, L., Ting, D. T., Bardeesy, N., Hong, T. S., Fernandez-del Castillo, C., Tanabe, K. K., Lillemoe, K. D., Ferrone, S., & Ferrone, C. R.
Venue
Clinical Cancer Research
Published
2016-01-14
Volume
22
Issue
2
Pages
470-478
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1949964307
Cited by
216
References
5
FWCI
16.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0715
The paper
Sabbatino, F., Villani, V., Yearley, J. H., Deshpande, V., Cai, L., Konstantinidis, I. T., Moon, C., Nota, S., Wang, Y., Al-Sukaini, A., Zhu, A. X., Goyal, L., Ting, D. T., Bardeesy, N., Hong, T. S., Fernandez-del Castillo, C., Tanabe, K. K., Lillemoe, K. D., Ferrone, S., & Ferrone, C. R. (2016). PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0715

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.